Rechallenge therapy versus tyrosine kinase inhibitor (TKI) for advanced metastatic colorectal cancer: a retrospective study
Abstract Currently, the standard third-line treatment options for advanced metastatic colorectal cancer (mCRC) include regorafenib, fruquintinib, and trifluridine/tipiracil (TAS-102), but these drugs have limited clinical efficacy. This study aims to evaluate the efficacy and survival outcomes of ty...
Saved in:
Main Authors: | Chenming Liu, Jintao Chen, Yuxing Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-02-01
|
Series: | Scientific Reports |
Subjects: | |
Online Access: | https://doi.org/10.1038/s41598-025-86575-x |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immunotherapy in metastatic renal cell carcinoma: Insights from a Dutch nationwide cohort
by: Hilin Yildirim, et al.
Published: (2025-02-01) -
Tumor characteristics and survival rate of axillary metastatic breast cancer patients: a three decades retrospective cohort study
by: Seyed Mohamad Sadegh Mousavi-kiasary, et al.
Published: (2025-02-01) -
Survival and risk factors for metastatic colorectal cancer patients with a history of prior malignancy
by: Yiwen Qiu, et al.
Published: (2025-02-01) -
Evaluating the surgical and oncological outcomes of hepatic artery variations in minimally invasive pancreaticoduodenectomy: insights from 2023 data at a high-volume pancreatic center
by: Tianyu Li, et al.
Published: (2025-02-01) -
Multiparameter body composition analysis on chest CT predicts clinical outcomes in resectable non-small cell lung cancer
by: Yilong Huang, et al.
Published: (2025-02-01)